Guerbet's Telebrix 38 replacements approved:
This article was originally published in Clinica
The French Health Ministry has officially withdrawn approval for Guerbet's Telebrix 38 X-ray contrast agent. The company decided to withdraw the products from sale last January as a "cautious move" following several reports of crystallisation (see Clinica No 638, p 14). The Ministry published approval for Guerbet's Telebrix 30 and Telebrix 35 contrast agents in the same ruling (Official journal of May 5th, 1995).
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.